Liver transplantation outcomes for early-stage hepatocellular carcinoma: Results of a multicenter study

被引:114
|
作者
Leung, JY
Zhu, AX
Gordon, FD
Pratt, DS
Mithoefer, A
Garrigan, K
Terella, A
Hertl, M
Cosimi, AB
Chung, RT
机构
[1] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA
[3] Massachusetts Gen Hosp, Transplant Unit, Boston, MA 02114 USA
[4] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA
[5] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA
[6] Tufts Univ, New England Med Ctr, Boston, MA 02111 USA
[7] Lahey Clin Fdn, Burlington, MA 01805 USA
关键词
D O I
10.1002/lt.20311
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The incidence of hepatocellular carcinoma (HCC), a frequent and incurable complication of cirrhosis, continues to rise. Orthotopic liver transplantation (OLT) has been proposed as a treatment for unresectable, intrahepatic HCC limited in extent to the Milan criteria adopted by the United Network of Organ Sharing (UNOS) in 1998. More recently, somewhat less restrictive University of California, San Francisco (UCSF)(10), criteria were proposed. To examine the long-term outcomes of OLT for HCC patients and to assess the UNOS policy of assigning weighted allocation points to patients with HCC, we retrospectively analyzed 144 patients (113 after 1998) with HCC who underwent OLT over an 11-year period at 3 institutions from UNOS Region 1. We compared their outcomes with 525 patients (272 after 1998) who underwent OLT for nonmalignant liver disease. The 1- and 5-year survival rates were 80.3% and 46.7%, respectively, for patients with HCC and 81.5% and 70.6%, respectively, for patients without HCC (P =.020). However, there was no difference in survival between HCC and non-HCC patients after implementation of disease-specific allocation for HCC in 1998. A higher proportion of the HCC cohort was older and male and had chronic HCV infection and alcoholic liver disease. In univariate analysis, having alpha-fetoprotein (AFP) levels of 10 ng/mL or less and meeting clinical and pathologic UCSF criteria were each significant predictors of improved survival (P =.005, P =.02, and P =.03, respectively). AFP greater than 10 ng/mL and exceeding pathologic UCSF criteria were also significant predictors of recurrence (P =.003 and P =.02, respectively). In conclusion, taken together, our data suggest that OLT is an acceptable option for patients with early HCC and that UCSF criteria predict outcome better than Milan or UNOS criteria. Regardless of which criteria are adopted to define eligibility, strict adherence to the criteria is important to achieve acceptable outcomes.
引用
收藏
页码:1343 / 1354
页数:12
相关论文
共 50 条
  • [21] Liver Transplantation for Hepatocellular Carcinoma: Results from a Multicenter Latin-American Study
    Pinero, Federico
    Andriani, Oscar
    de Atide, Elaide
    Marciano, Sebastian
    Orozco, Federico
    Zerega, Alina
    Diaz, Juan
    Maldonado, Carlos
    Chaman, Jose
    Menendez, Josemaria
    Zapata, Rodrigo
    Munoz, Linda
    Maraschio, Martin
    Longatto, Yuri
    Gerona, Sol
    Machaca, Martin Padilla
    Jarufe, Nicolas
    Gil, Octavio
    de Santibanes, Eduardo
    Mastai, Ricardo
    Soza, Alejandro
    Poniachik, Jaime
    McCormack, Lucas
    Gadano, Adrian
    Boin, Ilka
    Podesta, Luis
    TRANSPLANTATION, 2015, 99 : 120 - 120
  • [22] Treatment stage migration for early hepatocellular carcinoma and its impact on outcomes: A multicenter study
    Loo, K. F.
    Woodman, R.
    Bogatic, D.
    Muller, K.
    Chandran, V.
    Chinnaratha, M. A.
    Bate, J.
    Campbell, K.
    Maddison, M.
    Narayana, S.
    Le, H.
    Pryor, D.
    Wigg, A.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 : 67 - 68
  • [23] Is liver transplantation superior to resection in early stage hepatocellular carcinoma?
    Weimann, A
    Schlitt, HJ
    Oldhafer, KJ
    Hoberg, S
    Tusch, G
    Raab, R
    TRANSPLANTATION PROCEEDINGS, 1999, 31 (1-2) : 500 - 501
  • [24] Liver transplantation for combined hepatocellular carcinoma and cholangiocarcinoma: A multicenter study
    Kim, Jongman
    Joo, Dong-Jin
    Hwang, Shin
    Lee, Jeong-Moo
    Ryu, Je-Ho
    Nah, Yang-Won
    Kim, Dong-Sik
    Kim, Doo-Jin
    You, Young-Kyoung
    Yu, Hee-Chul
    WORLD JOURNAL OF GASTROINTESTINAL SURGERY, 2023, 15 (07): : 1340 - 1353
  • [25] Circulating tumor cells are associated with poor outcomes in early-stage hepatocellular carcinoma: a prospective study
    Ha, Yeonjung
    Kim, Tae Hun
    Shim, Jae Eul
    Yoon, Sunghyun
    Jun, Mi Jung
    Cho, Young-Ho
    Lee, Han Chu
    HEPATOLOGY INTERNATIONAL, 2019, 13 (06) : 726 - 735
  • [26] Circulating tumor cells are associated with poor outcomes in early-stage hepatocellular carcinoma: a prospective study
    Yeonjung Ha
    Tae Hun Kim
    Jae Eul Shim
    Sunghyun Yoon
    Mi Jung Jun
    Young-Ho Cho
    Han Chu Lee
    Hepatology International, 2019, 13 : 726 - 735
  • [27] Hepatocellular carcinoma: early-stage management challenges
    Erstad, Derek J.
    Tanabe, Kenneth K.
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2017, 4 : 81 - 92
  • [28] Exosomal miRNA in early-stage hepatocellular carcinoma
    Zhi-Qiang Wu
    Yi-Xin Zhu
    Yun Jin
    Yin-Chu Zhan
    World Journal of Clinical Cases, 2023, (03) : 528 - 533
  • [29] Exosomal miRNA in early-stage hepatocellular carcinoma
    Wu, Zhi-Qiang
    Zhu, Yi-Xin
    Jin, Yun
    Zhan, Yin-Chu
    WORLD JOURNAL OF CLINICAL CASES, 2023, 11 (03) : 528 - 533
  • [30] Treatment Options for Early-Stage Hepatocellular Carcinoma
    Tabori, Nora E.
    Sivananthan, Gajan
    SEMINARS IN INTERVENTIONAL RADIOLOGY, 2020, 37 (05) : 448 - 455